Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bayer AGFRA:BAYA -1.67%60 Shiller PE Ratio is 65.56 as of Aug. 22, 2026, which is 280% above its 10-year median of 17.24. GuruFocus rates FRA:BAYA with a GF Score™ of 60/100 and a GF Value™ of €6.74 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 529 Drug Manufacturers companies, Bayer AG ranks worse than 88.09% on this metric.
As of today (2026-08-22), Bayer AG's current share price is €11.80. Bayer AG's E10 for the quarter that ended in Jun. 2026 was €0.18. Bayer AG's Shiller PE Ratio for today is 65.56.
The historical rank and industry rank for Bayer AG's Shiller PE Ratio or its related term are showing as below:
FRA:BAYA'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.07 Med: 17.24 Max: 76.23
Current: 68.2
During the past years, Bayer AG's highest Shiller PE Ratio was 76.23. The lowest was 10.07. And the median was 17.24.
FRA:BAYA's Shiller PE Ratio is ranked worse than 88.09% of 529
companies
in the Drug Manufacturers industry
Industry Median: 25.6
vs FRA:BAYA: 68.20
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Bayer AG's adjusted earnings per share data for the three months ended in Jun. 2026 was €0.058. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €0.18 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Bayer AG Shiller PE Ratio Related Terms
Bayer AG Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Bayer AG's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BAYA vs LLY, JNJ, ABBV: Shiller PE Ratio Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Bayer AG's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Bayer AG's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG's E10 for the quarter that ended in Jun. 2026 is calculated as:
For example, Bayer AG's adjusted earnings per share data for the three months ended in Jun. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Bayer AG (FRA:BAYA) has a Shiller PE Ratio of 65.56 as of Aug. 22, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Bayer AG and its competitors. This is 280% above median its historical median of 17.24. Over the past decade, Bayer AG's Shiller PE Ratio has ranged from 10.07 to 76.23. According to the industry distribution chart, Bayer AG ranks #466 out of 529 companies in the Drug Manufacturers industry, placing it in the top 88.1%.
Is Bayer AG's Shiller PE Ratio too high?
Bayer AG's current Shiller PE Ratio of 65.56 is 280% above median its 10-year median of 17.24. Over the past 10 years, this metric has ranged from a low of 10.07 to a high of 76.23. The Drug Manufacturers industry median Shiller PE Ratio is 25.60. Bayer AG's value of 65.56 is 156.1% above this industry median. Based on the distribution chart, Bayer AG ranks #466 out of 529 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bayer AG has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Shiller PE Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #466 out of 529 companies for Shiller PE Ratio. This places Bayer AG in the lower half of its industry. The industry median Shiller PE Ratio is 25.60. Bayer AG's value of 65.56 is 156.1% above this benchmark. Historically, Bayer AG's own Shiller PE Ratio has ranged from 10.07 to 76.23 over the past decade. While the company's 10-year median is 17.24 vs. the industry median of 25.60, Bayer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.60, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current Shiller PE Ratio of 65.56 is 156.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current Shiller PE Ratio is 65.56, which is 280% above median its own 10-year median of 17.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (FRA:BAYA) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.74, compared to a current price of €11.80 — trading 75.1% above its estimated fair value. The current Shiller PE Ratio is 65.56, which is 280% above median its 10-year median of 17.24 and 156.1% above the Drug Manufacturers industry median of 25.60. Bayer AG's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Bayer AG (FRA:BAYA), the current Shiller PE Ratio is 65.56 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (FRA:BAYA) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of €11.80 is trading 75.1% above its estimated GF Value™ of €6.74.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for FRA:BAYA:
Shiller PE Ratio: 65.56 (280% above median its 10-year median of 17.24)
GF Value™: €6.74 vs. price of €11.80 (75.1% above fair value)
Industry Position: 156.1% above the Drug Manufacturers median (#466 of 529)
No single metric tells the full story. See the FRA:BAYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
60GF Score
Get the complete analysis for FRA:BAYA
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BAYA has been successfully added to your 
